Drug Safety Research Unit

The Drug Safety Research Unit (DSRU) is the UK’s leading pharmacovigilance and pharmacoepidemiology unit and is internationally respected for its work in Pharmacovigilance, Pharmacoepidemiology, Risk Management and Risk Minimisation. The DSRU’s experienced team of epidemiologists, clinicians and pharmacovigilance specialists conducts a broad range of real-world studies using a variety of study methods.

Our observational studies include CPRD studies, post-authorisation safety studies (PASS) in primary and secondary care, registries (including for the Early Access to Medicines Scheme, EAMS), European network studies, systematic reviews and benefit-risk assessments. We can also design and implement additional risk minimisation measures and monitor their effectiveness.

As a UK service provider, the DSRU is ideally placed to conduct observational studies in the UK. We have a deep understanding of the special characteristics of the UK population and National Health Service (NHS). The DSRU team has conducted studies for most of the world’s top 10 pharma companies and many small and medium sized companies.

In addition, DSRU Consultancy provides advice on strategies, study designs and options for post-marketing Pharmacovigilance, Pharmacoepidemiology, Risk Minimisation and Risk Management Planning in Europe for large and small pharma companies.

DSRU Education & Training is a leading European provider of training in Pharmacovigilance, Pharmacoepidemiology and Risk Management. Our portfolio of short courses can be used for one-off training or as part of our part-time postgraduate programme, leading to postgraduate certificate, diploma or MSc in Pharmacovigilance.